Muaiad Kittaneh, Head of R&D and Scientific Strategy, shared a post on LinkedIn by Jacquelyn Ritchie, Drug Development Leader at Syneos Health, adding:
“In oncology, ‘what’s next’ and ‘what’s needed’ are not always the same thing.
We continue to see remarkable innovation across modalities, biomarkers and increasingly sophisticated trial designs. But scientific innovation only translates into better therapies when we can answer the harder development questions: which patients, which biology, which endpoints- and what evidence will actually change clinical practice?
These are exactly the kinds of conversations that matter as the oncology community looks toward ESMO 2026 and ones our team at Syneos Health continues to have with sponsors and partners across the development continuum.”
Quoting Jacquelyn Ritchie’s post:
“See the latest in thinking on what is needed in Oncology in our weekly sync report below.
Looking forward to connecting with many of you in Madrid for ESMO in a few short weeks. We will have an amazing team onsite to talk about what is next vs what is needed!”
Other articles featuring Muaiad Kittaneh on OncoDaily.